CD274 and gastroesophageal junction adenocarcinoma: The INFINITY trial (NCT04817826), a phase II study, evaluated neoadjuvant durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) in patients with resectable MSI-H gastric or gastroesophageal junction adenocarcinoma.